Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Asıl Yazarlar: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Elsevier
2019
|
Benzer Materyaller
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Yazar:: Theodora Markati, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
Yazar:: Marshall W. Hogarth, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
Yazar:: Fatima Amor, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01) -
Genetic modifiers of respiratory function in Duchenne muscular dystrophy
Yazar:: Luca Bello, ve diğerleri
Baskı/Yayın Bilgisi: (2020-05-01) -
Duchenne Muscular Dystrophy
Yazar:: J Gordon Millichap
Baskı/Yayın Bilgisi: (1989-05-01)